Health
Brelovitug: Experimental Hepatitis D Drug Meets Main Goal in Late-Stage Study
Mirum Pharmaceuticals' monoclonal antibody achieved viral reduction and normal liver enzymes in over half of patients at the 300mg dose, versus 0% in the delayed-treatment group.
Rohaan ·Brelovitug: Experimental Hepatitis D Drug Meets Main Goal in Late-Stage Study · Brelovitug: Experimental Hepatitis D Drug Meets Main Goal in Late-Stage Study